FHIT is up-regulated by inflammatory stimuli and inhibits prostaglandin E2-mediated cancer progression

Cancer Research

Volumn 66, Issue 5, 2006, Pages 2683-2690

  Mimori, Koshi ^a   Ishii, Hideshi ^b   Nagahara, Hisashi ^a   Sudo, Tomoya ^a   Yamashita, Keishi ^a   Inoue, Hiroshi ^a   Barnard, Graham F ^c   Mori, Masaki ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b JICHI MEDICAL UNIVERSITY   (Japan)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CARCINOGEN; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; FRAGILE HISTIDINE TRIAD PROTEIN; PONASTERONE A; PROSTAGLANDIN E2; SMALL INTERFERING RNA;

ANTINEOPLASTIC ACTIVITY; ARTICLE; ASSAY; CANCER GROWTH; CANCER INVASION; CATALYSIS; CELL PROLIFERATION; COLORECTAL CANCER; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE; GENETIC SUSCEPTIBILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS;

ACID ANHYDRIDE HYDROLASES; ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; CYCLOOXYGENASE 2; DINOPROSTONE; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSFECTION; UP-REGULATION;

EID: 33645047657     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-2509     Document Type: Article

References (29)

1. Huebner K, Croce CM. FRA3B and other common fragile sites: the weakest links. Nat Rev Cancer 2001;1:214-21.
2. Inoue H, Ishii H, Alder H, et al. Sequence of the FRA3B common fragile region: implications for the mechanism of FHIT deletion. Proc Natl Acad Sci U S A 1997;94:14584-9.
3. Ishii H, Mimori K, Inageta T, et al. Components of DNA damage checkpoint pathway regulate UV exposure-dependent alterations of gene expression of FHIT and WWOX at chromosome fragile sites. Mol Cancer Res 2005;3:130-8.
4. Mimori K, Druck T, Inoue H, et al. Cancer-specific chromosome alterations in the constitutive fragile region FRA3B. Proc Natl Acad Sci U S A 1999;96:7456-61.
5. Mori M, Mimori K, Masuda T, et al. Absence of Msh2 protein expression is associated with alteration in the FHIT locus and FHIT protein expression in colorectal carcinoma. Cancer Res 2001;61:7379-82.
6. Nelson HH, Wiencke JK, Gunn L, Wain JC, Christiani DC, Kelsey KT. Chromosome 3p14 alterations in lung cancer: evidence that FHIT exon deletion is a target of tobacco carcinogens and asbestos. Cancer Res 1998;58:1804-7.
7. Sozzi G, Sard L, De Gregorio L, et al. Association between cigarette smoking and FHIT gene alterations in lung cancer. Cancer Res 1997;57:2121-3.
8. Sozzi G, Pastorino U, Moiraghi L, et al. Loss of FHIT function in lung cancer and preinvasive bronchial lesions. Cancer Res 1998;58:5032-7.
9. Stein CK, Glover TW, Palmer JL, Glisson BS. Direct correlation between FRA3B expression and cigarette smoking. Genes Chromosomes Cancer 2002;34:333-40.
10. Tseng JE, Kemp BL, Khuri FR, et al. Loss of Fhit is frequent in stage I non-small cell lung cancer and in the lungs of chronic smokers. Cancer Res 1999;59:4798-803.
11. Mori M, Mimori K, Shiraishi T, et al. Altered expression of Fhit in carcinoma and precarcinomatous lesions of the esophagus. Cancer Res 2000;60:1177-82.
12. Ishii H, Ozawa K, Furukawa Y. Alteration of the fragile histidine triad gene early in carcinogenesis: an update. J Exp Ther Oncol 2003;3:291-6.
13. Ishii H, Dumon KR, Vecchione A, et al. Potential cancer therapy with the fragile histidine triad gene: review of the preclinical studies. JAMA 2001;286:2441-9.
14. Ishii H, Dumon KR, Vecchione A, et al. Effect of adenoviral transduction of the fragile histidine triad gene into esophageal cancer cells. Cancer Res 2001;61:1578-84.
15. Woods JM, Mogollon A, Amin MA, Martinez RJ, Koch AE. The role of COX-2 in angiogenesis and rheumatoid arthritis. Exp Mol Pathol 2003;74:282-90.
16. Druck T, Hadaczek P, Fu TB, et al. Structure and expression of the human FHIT gene in normal and tumor cells. Cancer Res 1997;57:504-12.
17. Moraitis D, Du B, De Lorenzo MS, et al. Levels of cyclooxygenase-2 are increased in the oral mucosa of smokers: evidence for the role of epidermal growth factor receptor and its ligands. Cancer Res 2005;65:664-70.
18. Livneh E, Prywes R, Kashles O, et al. Reconstitution of human epidermal growth factor receptors and its deletion mutants in cultured hamster cells. J Biol Chem 1986;261:12490-7.
19. Nagahara H, Mimori K, Ohta M, et al. Somatic mutations of epidermal growth factor receptor in colorectal carcinoma. Clin Cancer Res 2005;11:1368-71.
20. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994;107:1183-8.
21. Soumaoro LT, Uetake H, Higuchi T, Takagi Y, Enomoto M, Sugihara K. Cyclooxygenase-2 expression: a significant prognostic indicator for patients with colorectal cancer. Clin Cancer Res 2004;10:8465-71.
22. + T cells. J Immunol 2005;175:1483-90.
23. 2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med 2002;8:289-93.
24. 2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. J Biol Chem 2003;278:35451-7.
25. Leng J, Han C, Demetris AJ, Michalopoulos GK, Wu T. Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through Akt activation: evidence for Akt inhibition in celecoxib-induced apoptosis. Hepatology 2003;38:756-68.
26. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995;83:493-501.
27. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998;93:705-16.
28. Tsujii M, Kawano S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci U S A 1997;94:3336-40.
29. Dannenberg AJ, Lippman SM, Mann JR, Subbaramaiah K, DuBois RN. Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. J Clin Oncol 2005;23:254-66.